About 29 million people worldwide are currently affected by the Opioid Use Disorder (OUD), which is caused by inappropriate use of opioids. In the United States, more than 2.5 million people rely on opioids and the number of drug-abuse deaths has increased by 21% from 52,404 in 2015 to 63,632 in 2016. Unfortunately, the crisis keeps aggravating. According to this, the United States has defined the Opioid Use Disorder (OUD) as a serious epidemic. In April 2017, the U.S. President, Donald Trump, regarded the crisis as a state of emergency and authorized the U.S. governments at all levels to use resources and public power to actively intervene the deterioration of the Opioid Use Disorder (OUD).
Buprenorphine is a very safe and effective drug for treatment of OUD patients. FP-004 developed by Foresee for treatment of opioid addiction is also long-acting and pre-filled in the syringe. It can be directly injected without the need for dissolution and mixing steps. The developed formulations include: 1-month long-acting injections and 3-month long-acting injections. Because of the sustained-release property, they can maintain the effective level of the ingredients in the blood, thereby reducing side effects and avoiding treatment interruption, instability and misappropriation of oral formulations. Thus, they can be more accepted by doctors and patients compared with existing products. FP-004 may also be indicated for chronic pain conditions such as low back, osteoarthritis, and neuropathic pain.